29/08/2026
𝐀𝐧𝐭𝐢𝐜𝐨𝐚𝐠𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐂𝐊𝐃 𝐟𝐨𝐫 𝐀𝐭𝐫𝐢𝐚𝐥 𝐅𝐢𝐛𝐫𝐢𝐥𝐥𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐕𝐞𝐧𝐨𝐮𝐬 𝐓𝐡𝐫𝐨𝐦𝐛𝐨𝐞𝐦𝐛𝐨𝐥𝐢𝐬𝐦: 𝟐𝟎𝟐𝟔 𝐄𝐒𝐂 𝐆𝐮𝐢𝐝𝐞𝐥𝐢𝐧𝐞𝐬
Anticoagulation in patients with chronic kidney disease (CKD) should be highly individualized, taking into account kidney function, indication for anticoagulation, thromboembolic risk, bleeding risk, and the characteristics of the available oral anticoagulants.
𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐖𝐢𝐭𝐡 𝐕𝐞𝐧𝐨𝐮𝐬 𝐓𝐡𝐫𝐨𝐦𝐛𝐨𝐞𝐦𝐛𝐨𝐥𝐢𝐬𝐦 (𝐕𝐓𝐄)
Goal: Treatment of VTE and prevention of recurrent VTE.
eGFR 30–59 : A DOAC (Factor Xa inhibitor or direct thrombin inhibitor) is preferred over LMWH or a VKA — Class I.
eGFR 15–29 mL: A Factor Xa inhibitor is preferred over LMWH or a VKA — Class IIb.
eGFR